Comparison of Four Early Posttherapy Imaging Changes (EPTIC; RECIST 1.0, Tumor Shrinkage, Computed Tomography Tumor Density, Choi Criteria) in Assessing Outcome to Vascular Endothelial Growth Factor–Targeted Therapy in Patients With Advanced Renal Cell Carcinoma-Reference-Cited by-同舟云学术

Comparison of Four Early Posttherapy Imaging Changes (EPTIC; RECIST 1.0, Tumor Shrinkage, Computed Tomography Tumor Density, Choi Criteria) in Assessing Outcome to Vascular Endothelial Growth Factor–Targeted Therapy in Patients With Advanced Renal Cell Carcinoma

Published:2011-05 Issue:5 Volume:59 Page:856-862
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Krajewski Katherine M.,Guo Mengye,Van den Abbeele Annick D.,Yap Jeffrey,Ramaiya Nikhil,Jagannathan Jyothi,Heng Daniel Y.C.,Atkins Michael B.,McDermott David F.,Schutz Fabio A.B.,Pedrosa Ivan,Choueiri Toni K.

Publisher

Elsevier BV

Subject

Urology

Reference18 articles.

1. Pathological evidence of necrosis in recurrent renal mass following treatment with sunitinib;Baccala;Int J Urol,2007

2. The loss of radiographic enhancement in primary renal cell carcinoma tumors following multitargeted receptor tyrosine kinase therapy is an additional indicator of response;Cowey;Urol,2010

3. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cell carcinoma;Yang;N Engl J Med,2003

4. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma;Motzer;N Engl J Med,2007

5. Sorafenib in advanced renal cell carcinoma;Escudier;N Engl J Med,2007

Cited by 99 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT;Health Technology Assessment;2024-08

2. Tumor shrinkage patterns of nivolumab monotherapy in metastatic renal cell carcinoma;International Journal of Urology;2022-06-18

3. Deciphering Intratumoral Molecular Heterogeneity in Clear Cell Renal Cell Carcinoma with a Radiogenomics Platform;Clinical Cancer Research;2021-07-01

4. Radiomics Response Signature for Identification of Metastatic Colorectal Cancer Sensitive to Therapies Targeting EGFR Pathway;JNCI: Journal of the National Cancer Institute;2020-02-04

5. Automated Identification of Optimal Portal Venous Phase Timing with Convolutional Neural Networks;Academic Radiology;2020-02